Sarepta Therapeutics (SRPT) Tops Q1 EPS by 75c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $0.73, $0.75 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $413.5 million versus the consensus estimate of $379.15 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Sysco raises mid-term targets, unveils $500M AI efficiency program
• Alcoa proposes $2.6B notes offering to fund South32 asset deal